While only BNP/NT-proBNP and autoantibodies are routinely used in SSc-PAH clinically, the emerging body of literature suggests that addition of additional serologic tests which incorporate aspects of altered inflammation, metabolism, and endothelial damage into assessment may be able to improve screening, diagnosis, and monitoring. This evidence concerns the gene NPPB and pulmonary arterial hypertension.